Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bepecin - PharmaCotherapia

Next Previous
X
Search
Drug Profile

Bepecin - PharmaCotherapia

Alternative Names: BPC 15; BPC-157; PCO-02; PL 10; PLD 116; PLD 14736

Latest Information Update: 22 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Zagreb
  • Developer PharmaCotherapia; PLIVA d.d.
  • Class Anti-inflammatories; Antiallergics; Antiulcers; Cytoprotectives; Peptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Ulcerative colitis

Most Recent Events

  • 06 May 2023 Pharmacodynamics data from preclinical trial in Ulcerative colitis presented at the Digestive Disease Week (DDW-2023)
  • 28 Nov 2018 No recent reports of development identified for phase-I development in Ulcerative-colitis(In volunteers) in Mexico (PO, Tablet)
  • 01 Oct 2015 Phase-I clinical trials in Ulcerative colitis (In volunteers) in Mexico (PO) (NCT02637284)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top